Scinai Immunotherapeutics Ltd. American Depositary Shares (SCNI) is a publicly traded Healthcare sector company. As of May 20, 2026, SCNI trades at $0.48 with a market cap of $2.22M and a P/E ratio of 0.00. SCNI moved -3.56% today. Year to date, SCNI is -30.35%; over the trailing twelve months it is -81.98%. Its 52-week range spans $0.45 to $6.18. Rallies surfaces SCNI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in SCNI news today?
Scinai Appoints Eilon Elmalem as Yavne CDMO Site Head Effective June 14, 2026: Scinai Biopharma Services has appointed Eilon Elmalem as Site Head of its Yavne CDMO facility, effective June 14, 2026, where he will oversee operations and engineering activities. Elmalem brings over 20 years of biopharma engineering and operations leadership from roles at Merck and Sigma-Aldrich Millipore, supporting planned facility expansion.
BEATY ELWIN M bought 80.00K (~$5.20K) on Dec 14, 2007.
BEATY ELAINE E bought 80.00K (~$5.20K) on Dec 14, 2007.
BEATY ELWIN M sold 80.00K (~$5.20K) on Dec 14, 2007.
SCNI Analyst Consensus
SCNI analyst coverage data. Average price target: $0.00.
Common questions about SCNI
What changed in SCNI news today?
Scinai Appoints Eilon Elmalem as Yavne CDMO Site Head Effective June 14, 2026: Scinai Biopharma Services has appointed Eilon Elmalem as Site Head of its Yavne CDMO facility, effective June 14, 2026, where he will oversee operations and engineering activities. Elmalem brings over 20 years of biopharma engineering and operations leadership from roles at Merck and Sigma-Aldrich Millipore, supporting planned facility expansion.
Does Rallies summarize SCNI news?
Yes. Rallies summarizes SCNI news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is SCNI research on Rallies investment advice?
No. Rallies provides research, data, and educational context for SCNI. It does not provide personalized investment advice.
